Long-Term Resveratrol Supplementation as a Secondary Prophylaxis for Stroke

Table 1

Demographic and clinical characteristics.

Characteristics	Resveratrol 100 mg group; ()		Resveratrol 200 mg group; ()		Control group; ()
	Number	%	Number	%	Number	%
Gender
Females	32	39.51	21	38.18	37	40.22
Males	49	60.49	34	61.82	55	59.78
Age
55–60 years	4	4.94	2	3.63	5	5.43
61–65 years	54	66.67	35	63.64	59	64.13
>65 years	23	28.39	18	32.73	28	30.44
Average	65.03 ± 8.24		64.52 ± 8.05		64.78 ± 6.32
Risk factors
Obesity	31	38.27	21	38.18	39	42.39
Toxicants (coffee, tobacco, and alcohol)	37	45.68	23	41.82	42	45.65
Stress	41	50.62	29	52.73	47	51.09
HBP	64	79.01	43	78.18	72	78.26
Diabetes	12	14.63	9	16.36	14	15.22
Dyslipidemia	50	61.73	37	67.3	61	66.30
Diagnostic
Ischemic stroke	59	72.64	41	74.54	68	73.91
Hemorrhagic stroke	22	27.16	14	25.46	24	26.09
Time since stroke occurred
<3 months	10	12.35	7	12.73	11	11.96
3–6 months	46	56.79	30	54.54	50	54.35
6–12 months	25	30.86	18	32.73	31	33.70
Average (months)	5.08 ± 1.22		5.13 ± 1.14		5.17 ± 1.16